Genetic Signatures Ltd
ASX:GSS

Watchlist Manager
Genetic Signatures Ltd Logo
Genetic Signatures Ltd
ASX:GSS
Watchlist
Price: 0.235 AUD -2.08%
Market Cap: 53.4m AUD

Genetic Signatures Ltd
Change in Working Capital

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Genetic Signatures Ltd
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Genetic Signatures Ltd
ASX:GSS
Change in Working Capital
AU$1.2m
CAGR 3-Years
114%
CAGR 5-Years
57%
CAGR 10-Years
N/A
Genetic Technologies Ltd
ASX:GTG
Change in Working Capital
AU$1.8m
CAGR 3-Years
27%
CAGR 5-Years
11%
CAGR 10-Years
43%
Proteomics International Laboratories Ltd
ASX:PIQ
Change in Working Capital
AU$234.1k
CAGR 3-Years
251%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
T
Trajan Group Holdings Ltd
ASX:TRJ
Change in Working Capital
-AU$148.4m
CAGR 3-Years
-14%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Cryosite Ltd
ASX:CTE
Change in Working Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
E
EZZ Life Science Holdings Ltd
ASX:EZZ
Change in Working Capital
AU$417.9k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Genetic Signatures Ltd
Glance View

Genetic Signatures Ltd. engages in the research and commercialization of identifying individual genetic signatures to identify diseases and disabilities. The company is headquartered in Sydney, New South Wales. The company went IPO on 2015-03-31. The firm is engaged in research and commercialization of identifying individual genetic signatures to aid in the diagnosis of infectious diseases and the sale of associated products into the diagnostic and research marketplaces. The firm is focused on the development and commercialization of its platform technology, 3Base. The Company’s 3Base platform technology provides hospital and pathology laboratories the ability to screen for an array of infectious pathogens, with a degree of specificity, in a rapid throughput (time-to-result) environment. The company also manufactures a Polymerase Chain Reaction (PCR) based products for the detection of infectious diseases under the EasyScreen brand. The Company’s EasyScreen sample processing kits are used to perform 3Base conversion and nucleic acid extraction and purification.

GSS Intrinsic Value
0.769 AUD
Undervaluation 69%
Intrinsic Value
Price

See Also

What is Genetic Signatures Ltd's Change in Working Capital?
Change in Working Capital
1.2m AUD

Based on the financial report for Jun 30, 2025, Genetic Signatures Ltd's Change in Working Capital amounts to 1.2m AUD.

What is Genetic Signatures Ltd's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
57%

Over the last year, the Change in Working Capital growth was 155%. The average annual Change in Working Capital growth rates for Genetic Signatures Ltd have been 114% over the past three years , 57% over the past five years .

Back to Top